Dynamic modelling of infectious diseases: An application to the economic evaluation of influenza vaccination

PharmacoEconomics

Volumn 26, Issue 1, 2008, Pages 45-56

  Pradas Velasco, Roberto ^a,b   Antoñanzas Villar, Fernando ^b   Martínez Zárate, María Puy ^c  

^a Centro Sagrado Corazón   (Spain)

^b UNIVERSITY OF LA RIOJA   (Spain)

^c Dirección General de Salud Pública   (Spain)

Author keywords

Cost analysis; Influenza virus infections, prevention; Influenza virus vaccine, therapeutic use; Modelling

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; DISEASE PREDISPOSITION; EXPERIMENTAL MODEL; HEALTH CARE COST; HEALTH ECONOMICS; IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; PRIORITY JOURNAL; SPAIN; THEORETICAL MODEL;

EID: 37549025739     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826010-00005     Document Type: Article

References (55)

1. Soto J. Pharmacoeconomic studies: why, how, when and for what? [in Spanish]. Medifam 2001; 11 (3): 147-55
2. Drummond M, O'Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes [in Spanish]. Madrid: Díaz de Santos, 2001
3. Service of Evaluation of Health Technologies. Guide of economic evaluation in the sanitary sector [in Spanish]. Osteba: Vitoria-Gasteiz, 1999
4. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999; 18 (23): 3263-82
5. Rodrigo C. Glossary. In: Arístegui J, Corretger JM, Moraga F, et al., editors. Child vaccinations: from theory to practice [in Spanish]. Bilbao: Ciclo Editorial, 2004: 23-31
6. Lynd LD, Goeree R, O'Brien BJ. Antiviral agents for influenza. Pharmacoeconomics 2005; 23 (11): 1083-106
7. Sander B, Hayden FG, Gyldmark M, et al. Post-exposure influenza prophylaxis with oseltamivir. Pharmacoeconomics 2006; 24 (4): 373-86
8. Zill DG, Cullen MR. Differential equations with frontier values problems. 5th ed. Mexico: Thomson Learning, 2002
9. Blanchard P, Devaney RL, Hall GR. Differential equations [in Spanish]. Mexico: Internacional Thomson Editores, 1999
10. Klein M. Mathematical methods for economics. Boston (MA): Addison-Wesley, 1998
11. Braun M. Differential equations and their applications [in Spanish]. Mexico: Grupo Editorial Iberoamérica, 1990
12. Gestal JJ. Acute respiratory infections: influenza [in Spanish]. In: Piédrola G, del Rey J, Domínguez M, et al., editors. Preventive medicine and public health. 9th ed [in Spanish]. Barcelona: Ediciones Científicas y Técnicas, 1994: 491-516
13. Keeling, M. The mathematics of diseases. Plus Magazine 2001; (14). Cambridge (UK): University of Cambridge, 2001 [online]. Available from URL: http://pass.maths.org.uk/issue14/features/diseases/index-gifd.html [Accessed 2007 Oct 3]
14. Anderson RM, May RM. Population biology of infectious diseases: part I. Nature 1979; 280 (5721): 361-7
15. Anderson RM, May RM. Directly transmitted infectious diseases: control by vaccination. Science 1982; 215: 1053-160
16. Thieme HR, Yang J. An endemic model with variable reinfection rate and applications to influenza. Math Biosci 2002; 180: 207-35
17. Lavenu A, Valleron AJ, Carrat F. Exploring cross-protection between influenza strains by an epidemiological model. Virus Res 2004; 103 (1-2): 101-5
18. Boni MF, Gog JR, Andreasen V, et al. Influenza drift and epidemic size: the race between generating and escaping immunity. Theor Pop Biol 2004; 65: 179-91
19. National Centre of Epidemiology. Epidemiologic commentary about diseases of obligatory notification and system of microbiological information [in Spanish]. Bol Epidemol Semanal 2004; 12 (10): 101-6
20. Gil de Gómez MJ, López MJ. Influenza in the autonomous community of La Rioja: activity of the disease and evaluation of the vaccination campaign. Recommendation of anti-influenza vaccine for the 2001-2002 season [in Spanish]. Bol Epidemiol de La Rioja 2001; 165: 1167-71
21. Arrazola MP. Anti-influenza vaccination in adults. In: Vaccines recommendations. Investigation Group of Madrid. Boletín 3 [in Spanish]. Madrid: Asociación para la Formación e Investigación en Salud Pública, 2004: 33-46
22. Pumarola T, Marcos MA, Jiménez de Anta MT. Influenza quimioprofilaxis [in Spanish]. Vacunas 2002; 3 Suppl. 1: 24-7
23. Kincaid D, Cheney W. Numerical analysis: the mathematics of the scientific calculus [in Spanish]. Wilmington (DE): Addison Wesley Iberoamericana, 1994
24. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. New York: Oxford University Press, 1999
25. García de Codes A, Arrazola MP, de Juanes JR, et al. Anti-influenza vaccination in healthcare staff: strategies to increase the coverage in a general hospital [in Spanish]. Med Clín (Barc) 2004; 123 (14): 532-4
26. Martínez-Martínez F. Strategies and coverage of anti-influenza vaccination of primary care staff: retrospective study [in Spanish]. Vacunas 2004; 5 (2): 35-7
27. Pastor MA, Schwuarz H, Pedrera V, et al. Anti-influenza vaccination state of primary care staff [in Spanish]. Aten Primaria 2004; 33 (3): 161
28. Mayo E, Hernández V, Carrasco P, et al. Evolution of antiinfluenza vaccination in the community of Madrid between the years 1993 and 2001 [in Spanish]. Vacunas 2005; 6 (2): 41-5
29. Peña A, Martínez L, Urbiztondo L. Knowledge, attitude and beliefs of the primary care staff about anti-influenza vaccine and vaccination [in Spanish]. Vacunas 2005; 6 (2): 46-50
30. Das Gupta R, Guest JF. A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac® in the UK. Pharmacoeconomics 2002; 20 (7): 475-84
31. De Mateo S. The importance of surveillance to control and to prevent influenza [in Spanish]. Vacunas 2002; 3 Suppl. 1: 9-13
32. Salleras L, Domínguez A. Health and economic impact of an anti-influenza vaccination [in Spanish]. Vacunas 2002; 3 Suppl. 1: 38-46
33. García MA, Figueroa Y. Evaluation of an anti-influenza vaccination program in a labour setting [in Spanish]. MAPFRE Medicina 2001; 12 (1): 49-53
34. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161 (5): 749-59
35. Public Health Directorate. Influenza [in Spanish]. Ministerio de Sanidad y Consumo; 2004 [online]. Available from URL: http://www.msc.es [Accessed 2007 Nov 1]
36. Conesa A, Vilardell L, Muñoz R, et al. Analysis and classification of hospital emergencies through Ambulatory Patient Groups [in Spanish]. Gac Sanit 2003; 17 (6): 447-52
37. Pradas R, Antoñanzas F, Zoellner Y. Economic evaluation of anti-influenza vaccination by the firm medical services: a health perspective [in Spanish]. Pharmacoeconomics 2005; 2 (2): 55-63
38. Campins M, Farjas P, González D. Pharmacoeconomic model of anti-influenza vaccination in population aged over 64 years [in Spanish]. Vacunas 2004; 4 Suppl. 1: 35-41
39. General Council of Pharmaceutical Official Association. Madrid: Base de datos del Medicamento, 2005
40. Royal Decree 1605/1980, of 31st of July, on the premium rates for unemployment, social security and salary fund, and review of the copayments for some drugs [in Spanish]. Madrid: Official Bulletin of the State, number 186, 1980 Aug 4
41. Resolution, 2004 Aug 2, on the tarrifs for health services provided in La Rioja [in Spanish]. La Rioja: Official Bulletin of La Rioja, number 89, 2004 Aug 5
42. Database of unitary cost (CD Rom version) [in Spanish]. Barcelona: Soikos, 2004
43. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003; 23 (1): 76-82
44. Trotter CL, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal serogroup c conjugate (mcc) vaccines using a transmission dynamic model. Med Decis Making 2006; 26 (1): 38-47
45. Armstrong GL, Billah K, Rein DB, et al. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Pediatrics 2007; 119 (1): e22-9
46. Haber M, Barskey A, Baughman W, et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 2007; 25 (29): 5390-8
47. Arrazola MP, de Juanes JR, García de Codes A. Interpandemic control of influenza [in Spanish]. Vacunas 2005; 6 (2): 56-61
48. Godoy P. Avian influenza pandemic: a new challenge for public health [in Spanish]. Gac Sanit 2006; 20 (1): 4-8
49. Sandman PM, Lanard J. Avian influenza: how to inform [in Spanish]. Perspectivas de Salud: La revista de la Organización Panamericana de la Salud 2005; 10 (2): 2-9
50. De Mateo S, Larrauri A, Mesonero C. Influenza surveillance: new solutions to an old problem [in Spanish]. Gac Sanit 2006; 20 (1): 67-73
51. Ryan J, Zoellner Y, Gradl B, et al. Establishing the health economic impact of influenza vaccination within the European Union 25 countries. Vaccine 2006; 24: 6812-22
52. Batalla J, Urbiztondo M, Martínez M, et al. Incidence of adverse effects associated with systematic vaccination and vaccination programmes in Catalonia [in Spanish]. Vacunas 2003; 4 (4): 127-31
53. Allsup S, Gosney M, Haycox A, et al. Cost-benefit evaluation of routine influenza immunization in people 65-74 years of age. Health Tech Assess 2003; 7 (24): 1-65
54. Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis 2001; 33 (11): 1879-85
55. Martín JM. Analysis of a economic model about a populational anti-influenza vaccination strategy in healthy employees [in Spanish]. Rev Esp Salud Pública 2006; 80 (3): 219-31